National mass drug administration costs for lymphatic filariasis elimination.

"The authors have declared that no competing interests exist."

"Funding Sources These cost analyses not only identified how program resources were allocated, but data also were used to identify sources and amounts of funding for 5 of the 7 study countries. Funding was categorized as coming from national governments (excluding external donations for LF), international organizations (IDAs, NGOs, WHO), pharmaceutical companies and local communities (Table 7). As expected, the drug donations represent a large proportion of contributions to MDA programs, so that when MOH and partner contributions are examined from the perspective of Economic costs, the drug donations can make up over 90% (range 9%–99%) of the costs. This was particularly true in countries like Burkina Faso and Tanzania where both drugs used in the MDA (albendazole and Mectizan) were donated. When Financial costs are analyzed, however, it is clear that contributions from national governments represent a significant portion of the resources used to implement the MDAs (average = 56%, range 9%–99%). These relationships can be seen graphically in Figure 2 which presents the combined average of Financial and Economic funding sources for the Burkina Faso, the Dominican Republic, Egypt, the Philippines and Tanzania programs detailed in Table 7. 10.1371/journal.pntd.0000067.g002Figure 2Sources of Funding for the MDAs Conducted by National LF Elimination Programs in Burkina Faso, Dominican Republic, Egypt, the Philippines and Tanzania (Financial Costs and Economic Costs). 10.1371/journal.pntd.0000067.t007Table 7Sources of Funding for LF Elimination Costs.National ProgramYearNational GovernmentInternational Organizations (IDA,NGO,WHO)Pharma CompaniesCommunityPercentage of Program Costs (i.e., Financial Costs) for Each Source of Funds Albendazole+MectizanBurkina Faso200239%61%0%<1%Tanzania200355%45%0%<1%Albendazole+DECDominican Republic20039%91%0%<1%Egypt200080%20%0%<1%Philippines200399%<1%0%<1%Percentage of Total Costs (i.e., Economic Costs) for Each Source of Funds Albendazole+MectizanBurkina Faso2002<1%<1%99%<1%Tanzania20033%2%95%<1%Albendazole+DECDominican Republic1998–200346%42%9%3%Egypt200072.5%11.5%16%<1%Philippines200348%3%46%3%"